Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 to \<61 years of age~2. mentally competent to understand the nature, the scope and the consequences of the study~3. able and willing to give written informed consent prior to study entry~4. in good health as determined by:~   1. medical history,~  2. physical examination,~  3. clinical judgment of the Investigator.~Exclusion Criteria:~1. unwilling or unable to give written informed consent to participate in the study~2. participation in another clinical trial of an investigational agent within 90 days prior to Visit 1 and throughout the entire study~3. currently experiencing an acute infectious disease~4. any serious disease, such as, for example:~   1. cancer,~  2. autoimmune disease (including rheumatoid arthritis),~  3. advanced arteriosclerotic disease or complicated diabetes mellitus,~  4. chronic obstructive pulmonary disease (COPD) requiring oxygen therapy,~  5. acute or progressive hepatic disease,~  6. acute or progressive renal disease,~  7. congestive heart failure~5. surgery planned during the study period~6. bleeding diathesis~7. history of hypersensitivity to any component of the study medication or chemically related substances~8. history of any anaphylaxis, serious vaccine reactions, or allergy to any of the vaccine component~9. known or suspected impairment/alteration of immune function, for example resulting from:~   1. receipt of immunosuppressive therapy (any corticosteroid therapy or cancer chemotherapy),~  2. receipt of immunostimulants,~  3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within 3 months prior to Visit 1 or planned during the full length of the study,~  4. high risk for developing an immunocompromising disease~10. history of drug or alcohol abuse~11. laboratory-confirmed influenza disease within 6 months prior to Visit 1~12. receipt of influenza vaccine within 6 months prior to Visit 1~13. receipt of another vaccine within 60 days prior to Visit 1, or planned vaccination within 3 weeks following study vaccination~14. any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) or experienced fever (i.e., axillary temperature ≥ 38 degree C) within 5 days prior to Visit 1~15. if female, pregnant or breastfeeding~16. if female, refusal to use a reliable contraceptive method during the three weeks following vaccination~17. planned relocation abroad during the study period~18. any condition that, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- cTIV_lot 1 (Type: EXPERIMENTAL): None
- cTIV_lot 2 (Type: EXPERIMENTAL): None
- cTIV_lot 3 (Type: EXPERIMENTAL): None
- TIV group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete